Research into novel anxiolytics among selective carbonic anhydrase II inhibitors
https://doi.org/10.34215/1609-1175-2025-4-63-69
Abstract
Objective. To identify new anxiolytics among selective carbonic anhydrase II inhibitors.
Materials and methods. The study involved nine new selective carbonic anhydrase II (CAII) inhibitors, which are sulfonamide derivatives with laboratory codes B1–3, B10–13, B18, and B24. The open field, elevated plus maze, and tail suspension tests were used. Two types of animals were examined: mice and rats. Statistical processing was performed using Microsoft Excel and Biostatistics software.
Results. Both in experiments on rats and mice, compound B24 exhibits anxiolytic and antidepressant activity, while also enhancing the cognitive functions of animals. Compounds B10, B12, and B18 potentially possess anxiolytic effects, while B13 exhibits antidepressant activity.
Сonclusion. The study results indicate that new drugs from selective carbonic anhydrase II inhibitors possess anxiolytic and antidepressant activity while improving cognitive functions in animals.
About the Authors
O. E. Lazariants
Yaroslavl State Medical University;
Yaroslavl State Pedagogical University
Russian Federation
Russian Federation
Yaroslavl
V. N. Fedorov
Yaroslavl State Medical University;
Yaroslavl State Pedagogical University
Russian Federation
Russian Federation
Yaroslavl
A. A. Shetnev
Yaroslavl State Pedagogical University;
Moscow Institute of Physics and Technology
Russian Federation
Russian Federation
Yaroslavl
Moscow
A. V. Sapegin
Saint Petersburg State University
Russian Federation
Russian Federation
Saint Petersburg
S. Sh. Suleymanov
Russian-Japanese Medical Center
Russian Federation
Russian Federation
Salavat S. Suleymanov, Dr. Sci. (Med.), Prof., General Director
104 Komsomolskaya str., Khabarovsk, 680000, Russia
References
1. Zhao H, Zhou M, Liu Y, Jiang J, Wang Y. Recent advances in anxiety disorders: Focus on animal models and pathological mechanisms. Animal Model Exp Med. 2023;6(6):559–72. doi: 10.1002/ame2.12360
2. COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398(10312):1700–12. doi: 10.1016/S0140-6736(21)02143-7
3. Penninx BW, Pine DS, Holmes EA, Reif A. Anxiety disorders. Lancet. 2021;397(10277):914–27. doi: 10.1016/S0140-6736(21)00359-7
4. Ly C, Greb AC, Cameron LP, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Soltanzadeh Zarandi S, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, OriMcKenney KM, Gray JA, Olson DE. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23(11):3170–82. doi: 10.1016/j.celrep.2018.05.022
5. Javaid SF, Hashim IJ, Hashim MJ, Stip E, Samad MA, Ahbabi AA.Epidemiology of anxiety disorders: Global burden and sociodemographic associations. Middle East Current Psychiatry. 2023;30(1):44. doi: 10.1186/s43045-023-00315-3
6. Léonard C, Charriau-Perret A, Debaty G, Belle L, Ricard C, Sanchez C, Dupré PM, Panoff G, Bougerol T, Viglino D, Blancher M; Northern French-Alps Emergency Network (“RENAU”). Survivors of avalanche accidents: posttraumatic stress disorder symptoms and quality of life: A multicentre study. Scand J Trauma Resusc Emerg Med. 2021;29(1):96. doi:10.1186/s13049-021-00912-3
7. Ren L, Fan Y, Wu W, Qian Y, He M, Li X, Wang Y, Yang Y, Wen X, Zhang R, Li C, Chen X, Hu J. Anxiety disorders: Treatments, models, and circuitry mechanisms. Eur J Pharmacol. 2024;983:176994. doi: 10.1016/j.ejphar.2024.176994
8. Capiau A, Huys L, van Poelgeest E, van der Velde N, Petrovic M, Somers A; EuGMS Task, Finish Group on FRIDs. Therapeutic dilemmas with benzodiazepines and Z-drugs: Insomnia and anxiety disorders versus increased fall risk: A clinical review. Eur Geriatr Med. 2023;14(4):697–708. doi: 10.1007/s41999-022-00731-4
9. Goldschen-Ohm MP. Benzodiazepine modulation of GABAA receptors: A mechanistic perspective. Biomolecules. 2022;12(12):1784. doi: 10.3390/biom12121784A
10. Knight P, Chellian R, Wilson R, Behnood-Rod A, Panunzio S, Bruijnzeel AW. Sex differences in the elevated plus-maze test and large open field test in adult Wistar rats. Pharmacol Biochem Behav. 2021;204:173168. doi: 10.1016/j.pbb.2021.173168
11. Can A, Dao DT, Terrillion CE, Piantadosi SC, Bhat S, Gould TD. The tail suspension test. J Vis Exp. 2012;(59):e3769. doi: 10.3791/3769
12. Supuran CT. Coumarin carbonic anhydrase inhibitors from natural sources. J Enzyme Inhib Med Chem. 2020;35(1):1462–70. doi: 10.1080/14756366.2020.1788009
13. Mehrhoff EA, Booher WC, Hutchinson J, Schumacher G, Borski C, Lowry CA, Hoeffer CA, Ehringer MA. Diazepam effects on anxiety-related defensive behavior of male and female high and low open-field activity inbred mouse strains. Physiol Behav. 2023;271:114343. doi: 10.1016/j.physbeh.2023.114343
14. Pentkowski NS, Rogge-Obando KK, Donaldson TN, Bouquin SJ, Clark BJ. Anxiety and Alzheimer's disease: Behavioral analysis and neural basis in rodent models of Alzheimer's-related neuropathology. Neurosci Biobehav Rev. 2021;127:647–58. doi: 10.1016/j.neubiorev.2021.05.005
Review
For citations:
Lazariants O.E., Fedorov V.N., Shetnev A.A., Sapegin A.V., Suleymanov S.Sh. Research into novel anxiolytics among selective carbonic anhydrase II inhibitors. Pacific Medical Journal. 2025;(4):63-69. (In Russ.) https://doi.org/10.34215/1609-1175-2025-4-63-69
Views:
191
JATS XML
Email this article 